Treatment of Subclinical Antibody-mediated Acute Rejection in Kidney Transplant Recipients With the Complement Inhibitor Eculizumab
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2015
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TAMARCIN
- 24 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.